ISE:UPRHealthcare
Is Uniphar’s Rare-Disease Logistics Expansion with Zevra Reshaping the Investment Case for Uniphar (ISE:UPR)?
Zevra Therapeutics announced that it has entered into an exclusive expanded access distribution agreement with Ireland-based Uniphar, enabling Niemann-Pick Disease Type C patients in select territories outside Europe to obtain reimbursed named-patient supply of MIPLYFFA, the only approved therapy that targets the underlying pathology of this ultra-rare condition.
The deal strengthens Uniphar’s position as a specialist partner for complex rare-disease logistics, highlighting its capabilities...